Loss of FOXF2 Expression Predicts Poor Prognosis in Hepatocellular Carcinoma Patients

Annals of Surgical Oncology

Volumn 23, Issue 1, 2016, Pages 211-217

  Shi, Zhiyong ^a   Liu, Jie ^b   Yu, Xiaohe ^a   Huang, Jian ^a   Shen, Shuqun ^a   Zhang, Yongshun ^b   Han, Rongli ^c   Ge, Naijian ^a   Yang, Yefa ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b HUBEI UNIVERSITY OF MEDICINE   (China)

^c Dahua Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXF2; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXF2 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

ADULT; APOPTOSIS; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CELL PROLIFERATION; CHEMOEMBOLIZATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; RNA INTERFERENCE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TUMOR CELL CULTURE; TUMOR INVASION; TUMOR RECURRENCE;

APOPTOSIS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; FEMALE; FOLLOW-UP STUDIES; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 84952629754     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-015-4515-2     Document Type: Article

References (21)

1. A comment on ‘global activity of cancer registries and cancer control and cancer incidence statistics in Korea’. J Prev Med Public Health. 2008;41(3):208–209; author reply 209–11.
2. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist. 2010;15(Suppl 4):5–13.
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.
4. Bruix J, Sherman M. American association for the study of liver diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.
5. Katoh M, Katoh M. Human FOX gene family (review). Int J Oncol. 2004;25(5):1495–500.
6. Badve S, Turbin D, Thorat MA, et al. FOXA1 expression in breast cancer: correlation with luminal subtype A and survival. Clin Cancer Res. 2007;13(15 Pt 1):4415–21.
7. Lo PK, Lee JS, Liang X, et al. Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Res. 2010;70(14):6047–58.
8. Ray PS, Wang J, Qu Y, et al. FOXC1 is a potential prognostic biomarker with functional significance in basal-like breast cancer. Cancer Res. 2010;70(10):3870–6.
9. Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. FOXA1: growth inhibitor and a favorable prognostic factor in human breast cancer. Int J Cancer. 2007;120(5):1013–22.
10. Gong C, Fujino K, Monteiro LJ, et al. FOXA1 repression is associated with loss of BRCA1 and increased promoter methylation and chromatin silencing in breast cancer. Oncogene. doi:10.1038/onc.2014.421.
11. Liu J, Shen L, Yao J, et al. Forkhead box C1 promoter upstream transcript, a novel long non-coding RNA, regulates proliferation and migration in basal-like breast cancer. Mol Med Rep. 2015;11(4):3155–9.
12. Nik AM, Reyahi A, Ponten F, Carlsson P. Foxf2 in intestinal fibroblasts reduces numbers of Lgr5(+) stem cells and adenoma formation by inhibiting Wnt signaling. Gastroenterology. 2013;144(5):1001–11.
13. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G. Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int. 2009;103(11):1574–80.
14. Shi W, Gerster K, Alajez NM, et al. MicroRNA-301 mediates proliferation and invasion in human breast cancer. Cancer Res. 2011;71(8):2926–37.
15. Kong PZ, Yang F, Li L, Li XQ, Feng YM. Decreased FOXF2 mRNA expression indicates early-onset metastasis and poor prognosis for breast cancer patients with histological grade II tumor. PloS One. 2013;8(4):e61591.
16. Figueroa JD, Han SS, Garcia-Closas M, et al. Genome-wide interaction study of smoking and bladder cancer risk. Carcinogenesis. 2014;35(8):1737–44.
17. Hirata H, Ueno K, Shahryari V, et al. MicroRNA-182-5p promotes cell invasion and proliferation by down regulating FOXF2, RECK and MTSS1 genes in human prostate cancer. PloS One. 2013;8(1):e55502.
18. van den Brink GR, Rubin DC. Foxf2: a mesenchymal regulator of intestinal adenoma development. Gastroenterology. 2013;144(5):873–6.
19. Funamizu N, Lacy CR, Parpart ST, Takai A, Hiyoshi Y, Yanaga K. MicroRNA-301b promotes cell invasiveness through targeting TP63 in pancreatic carcinoma cells. Int J Oncol. 2014;44(3):725–34.
20. Cao G, Huang B, Liu Z, et al. Intronic miR-301 feedback regulates its host gene, ska2, in A549 cells by targeting MEOX2 to affect ERK/CREB pathways. Biochem Biophys Res Commun. 2010;396(4):978–82.
21. Aitola M, Carlsson P, Mahlapuu M, Enerback S, Pelto-Huikko M. Forkhead transcription factor FoxF2 is expressed in mesodermal tissues involved in epithelio-mesenchymal interactions. Dev Dyn. 2000;218(1):136–49.